about
The discovery of putative urine markers for the specific detection of prostate tumor by integrative mining of public genomic profiles.Therapy-induced senescence in cancerSerum total prostate-specific antigen values in men with symptomatic prostate enlargement in Nigeria: role in clinical decision-makingEvaluation of prediction models for the staging of prostate cancer.Noncoding RNAs that associate with YB-1 alter proliferation in prostate cancer cells.Tumor and Plasma Met Levels in Non-Metastatic Prostate Cancer.Statistical consideration for clinical biomarker research in bladder cancer.Tumor markers in prostate cancer I: blood-based markers.Ultrasensitive immunosensor for cancer biomarker proteins using gold nanoparticle film electrodes and multienzyme-particle amplification.Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas.Evaluation and characterization of anti-RalA autoantibody as a potential serum biomarker in human prostate cancer.Cancer and the metastatic substrate.Redox-mediated and ionizing-radiation-induced inflammatory mediators in prostate cancer development and treatment.Putative molecular signatures for the imaging of prostate cancer.Metabolomics: a novel approach to early and noninvasive prostate cancer detection.Molecular biomarkers in prostate cancer.The development of nomograms for stratification of men at risk of prostate cancer prior to prostate biopsy.The role of biomarkers in the assessment of prostate cancer risk prior to prostate biopsy: which markers matter and how should they be used?The prognostic role of preoperative serum C-reactive protein in predicting the biochemical recurrence in patients treated with radical prostatectomy.Predictive values for extracapsular extension in prostate cancer patients with PSA values below 10 ng/mL.Evaluating PSA Density as a Predictor of Biochemical Failure after Radical Prostatectomy: Results of a Prospective Study after a Median Follow-Up of 36 Months.Osteopontin is a tumor autoantigen in prostate cancer patients.Assays for prostate cancer : changing the screening paradigm?
P2860
Q34110104-902D0A94-491A-4FC4-81C8-CC39FAD0D5E8Q34212773-19ECFDC5-8AFF-4FFF-95DC-C55E32DA8DF1Q34823589-E6993EDD-33B3-43BB-ADE8-20EF5EC2E874Q35044520-487544CB-B415-4EE8-B328-501A29F8E6B5Q35621452-729DA72B-9E45-4D8E-847D-1AE522258E3AQ36051783-5DF4A397-C2FC-47A7-807C-33EC51F681D2Q36124883-412D8398-5BB3-4875-93D2-643D00C8F8FCQ36607766-25346B05-5C1E-4951-9C26-577541BBA913Q37153497-DE0D991B-9BED-461F-8109-84D6B76BD669Q37395331-4477F048-BF4C-4A38-9CAD-CB28FF9140F2Q37536632-E24FA1E4-3CD8-4BA3-9E96-BC58CF3FB996Q37573461-D9CE3E0A-4AB9-4D3D-8C50-800EFB8A6AF8Q37606662-44B6325D-D2C0-482D-BF74-79B5D5CE9614Q37656266-7790B60A-610E-4195-8D84-8809142B0305Q37850315-9B6C93EE-766F-4D73-9529-A0B2C13B21F9Q38088854-4923A3E1-EE40-4EA7-9ABC-DC23B465D560Q38165242-87EFF168-128F-4A95-BEE2-AE7748362C4BQ38211603-C3410A2C-D9EC-41B6-9232-9589099ABFF2Q40062405-06F3AD5A-7CBF-4382-8DF8-5C51BF2D685DQ40309757-1DC9FCC7-AF4B-4C9E-8128-317C3BBBC421Q41474507-3CF00F7C-1596-4FCF-8831-179CB27D3746Q41810965-CA0D54F1-D7DE-4F30-8C88-9F23EDBDFFF4Q46530327-1DE85726-DF4C-48C7-87A2-FAAE21F803A3
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
New circulating biomarkers for prostate cancer.
@en
type
label
New circulating biomarkers for prostate cancer.
@en
prefLabel
New circulating biomarkers for prostate cancer.
@en
P2093
P356
P1476
New circulating biomarkers for prostate cancer.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.PCAN.4501026
P577
2007-11-13T00:00:00Z